Treatment of Vasomotor Symptoms

Author/s: 
Karina Atwell, Morgan White, Greta Kuphal, Makeba Williams, Sarina Schrager
Date Added: 
February 25, 2025
Journal/Publication: 
The Journal of the American Board of Family Medicine
Publication Date: 
September 1, 2024
Issue: 
5
Volume: 
37
Pages: 
923-932
Type: 
Meta-analyses, Reviews, and Guidelines
Format: 
Article
DOI (1): 
https://doi.org/10.3122/jabfm.2023.230408R1
MeSH 

RPR Commentary

A review of treatment options for patients with vasomotor symptoms of menopause. James W. Mold, MD, MPH

Abstract

Vasomotor symptoms (VMS) related to the menopausal transition affect the majority of women and contribute to significant quality of life burden. Incidence, length, severity and report of symptoms vary by race, ethnicity, and coexisting health conditions. The pathophysiology of VMS is not fully understood and is likely multifactorial, involving changes in the hypothalamicpituitary-ovarian axis during the menopausal transition. Treatment approaches include lifestyle modifications, hormonal and non-hormonal therapies, including integrative and complementary medicine approaches. Systemic hormone therapy with estrogen is the most effective treatment. Emerging evidence suggests that treatment with SSRIs, SNRIs, and gabapentin is effective for many women who want to avoid hormone therapy. A shared decision approach to treatment decisions involves consideration of risks with treatment options and discussion of patient priorities.

Text Availability

Free full text